pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Blueprint Medicines Corp

updated 21d ago
Website ↗
community read0 votes
pipeline
4
marketed
2
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(4)

pipeline depth4 products
Phase 2: 1Phase 3: 1Marketed: 2
1Phase 21Phase 32Marketed
Marketed
avapritinib
Gastrointestinal Stromal Tumor (GIST)
Marketed
pralsetinib
Solid Tumor
Phase 3
elenestinib
Systemic Mastocytosis
Phase 2
BLU-808
Chronic Inducible Urticaria

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • —Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populationsrecruitingn=750
  • phase2A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutationsrecruitingn=265
  • phase3(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosisrecruitingn=534
  • —An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)recruitingn=150
  • phase2Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)active not recruitingn=105
  • phase2(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosiscompletedn=107
  • —A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germanyrecruitingn=80
  • phase1A Study of Elenestinib in Healthy Adult Female Participantscompletedn=20
more trials →
🐶 Hiring Signal
No open roles indexed yet — view Blueprint Medicines Corp jobs →

News

  • 7 biopharma M&A deals where layoffs followed
    Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired b…
    biospace · 1d ago
  • STAT+: Doritos as farm-to-table snacks? Big Food, under duress, gets creative
    Doritos in the classic nacho cheese flavor have 27 ingredients, including not just familiar ones but also a number of additives and preservatives.
    stat · 3d ago
  • STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
    Sanofi, one of the Massachusetts' largest pharmaceutical employers, will lay off more than 200 workers there a year after acquiring Blueprint Medicines.
    stat · 3d ago
identifiers
source
globaldata
top tags
Oncology3Dermatology1NSCLC1
mentioned in
3news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?